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Purpose: To report outcomes in breast cancer patients with prior breast augmenta-
tion treated with external beam accelerated partial breast irradiation (EB-APBI) utiliz-
ing intensity-modulated radiotherapy or 3-dimensional conformal radiotherapy, both with
IGRT.
Materials and Methods: Sixteen stage 0/1 breast cancer patients with previous elec-
tive bilateral augmentation were treated post-lumpectomy on institutional EB-APBI trials
(01185132 and 01185145 on clinicaltrials.gov). Patients received 38.5 Gy in 10 fractions over
five consecutive days. Breast/chest wall pain and cosmesis were rated by patient; cosmesis
was additionally evaluated by physician per RTOG criteria.
Results:The median follow-up from accelerated partial breast irradiation (APBI) completion
was 23.9 months (range, 1.2–58.6). Little to no change in cosmesis or pain from baseline
was reported. Cosmetic outcomes at last follow-up were judged by patients as excel-
lent/good in 81.2% (13/16), and by physicians as excellent/good in 93.8% (15/16). Ten
patients (62.5%) reported no breast/chest wall pain, five (31.2%) reported mild pain, and
one (6.2%) reported moderate pain. All patients remain disease free at last follow-up. The
median ipsilateral breast, planning target volume (PTV), and implant volumes were 614,
57, and 333 cm3.The median ratios of PTV/ipsilateral breast volume (implant excluded) and
PTV/total volume (implant included) were 9 and 6%.
Conclusion: These 16 breast cancer cases with prior bilateral augmentation treated with
EB-APBI demonstrate favorable clinical outcomes. Further exploration of EB-APBI as a
treatment option for this patient population is warranted.
Keywords: accelerated partial breast irradiation, breast augmentation mammoplasty, external beam radiotherapy,
image-guided radiotherapy, intensity-modulated radiotherapy
INTRODUCTION
The number of breast augmentation procedures in the United
States has increased by 35% over the previous 12 years to 286,274
in 2012 (1) and remains one of the most common cosmetic pro-
cedures. It is the second leading cosmetic surgical procedure and
the leading cosmetic surgery in women. Ninety percent of these
procedures are performed in women <50 years of age.
Reports on outcomes of whole breast irradiation in women
with previous augmentation (2–15) have described radiotherapy
(RT)-induced circumferential fibrosis around the implant, lead-
ing to capsular contraction or other complications in as high as
65% of patients and satisfactory cosmesis in as low as 1/3 of the
patients.
Accelerated partial breast irradiation (APBI) is currently under
study as a treatment option for early stage [Tis, T1, T2 (≤3 cm) N0
M0] breast cancer, with results pending from NSABP B-39/RTOG
0413 (16) and several other large randomized clinical trials.
Theoretically, APBI would decrease the implant surface area
exposed to radiation and thereby reduce the risk of capsular con-
tracture and unsatisfactory cosmesis. However, there is limited
data on the use of APBI in women who have had prior breast
augmentation in the affected breast (17–21). The largest data
series to date of APBI-treated augmented breasts utilized various
brachytherapy techniques (17). External beam APBI (EB-APBI)
using either 3-dimensional conformal radiotherapy (3D-CRT) or
intensity-modulated radiotherapy (IMRT) is increasingly being
investigated (16, 22, 23), but women with breast augmentation in
the affected breast were excluded from B-39 (16), and many ques-
tions regarding the feasibility of external beam APBI in this pop-
ulation remain unanswered: Would APBI using 3D-CRT/IMRT
planning cause complications specific to augmented breasts? Does
this technique result in acceptable cosmetic outcomes? Does the
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cosmetic outcome change over time? This report presents our
institutional experience to date of EB-APBI in the setting of
previous breast augmentation.
MATERIALS AND METHODS
Between April 2008 and November 2012, 16 newly diagnosed
stage 0 or 1 breast cancer patients with prior breast augmen-
tation were treated on one of two IRB-approved institutional
post-lumpectomy EB-APBI studies: Phase II APBI utilizing IMRT
(n= 3) or Phase III APBI randomized IMRT vs. 3D-CRT (n= 13);
both protocols utilized image-guided radiotherapy (IGRT). RT
planning and treatment details have been previously reported
(19, 23–25) and summarized here. RT planning included an ini-
tial computed tomographic (CT) simulation scan to ascertain the
location and size of the surgical cavity, which was designated as
the gross target volume (GTV). An additional margin of 1 cm
was contoured around the GTV to form the clinical target vol-
ume (CTV). The planning target volume (PTV) was formed by
adding an additional 0.5 cm around the CTV. The ipsilateral breast
volume was contoured from the clavicle to the inframammary fold
in the cranial–caudal direction, and medially/laterally from mid-
sternum to approximately the mid-axillary line. The CTV and PTV
volumes were at least 0.5 cm from the skin surface and were only
allowed to extend into the implant volume for 0.5 cm. CTV and
PTV were also at least 0.5 cm from the chest wall which included
the ribs, intercostal muscles, and pectoralis muscles between the
breast tissue and the lung/chest wall interface and was contoured
from the mid-sternum medially to the level of the latissimus dorsi
laterally. Ribs and muscular chest wall could be excluded from
both the PTV and CTV at the discretion of the treating physi-
cian. Finally, a wire was placed on the skin surface to indicate the
surgical scar to possibly aide in target definition.
Dose constraints for IMRT patients were as follows: The
PTV/ipsilateral breast volume ratio was generally limited to<20%.
Plans were optimized so that≥95% of the PTV received≥95% of
the prescribed dose. Heart exposure was limited to ≤5% organ
volume receiving >5% of the prescribed dose. Ipsilateral lung
exposure was initially limited to ≤15% receiving 30% of the
Table 1 | Patient characteristics.
Age at diagnosis (year) 40–49 7
50–59 5
≥60 4
Menopausal status (n) Pre/perimenopausal 7
Postmenopausal 9
Histology/grade (n) DCIS 6 Low 3
Intermediate 3
High 0
Invasive T1a 2 Low 6
T1b 6 Intermediate 3
T1c 2 High 1
Tumor span (cm) Median (range) 0.75 (0.2–3.0a)
Margin (cm) Median (range) 0.5 (0.2–1.5)
Breast laterality/quadrant (n) Right UO 5 Left UO 4
UI 2 UI 1
LO 0 LO 2
LI 1 LI 1
Position of implant (n) Retroglandular 1
Subpectoral 15
Type of implant (n) Saline 13
Silicon 3
Time from augmentation to RT (year) Median (range) 10.7 (2.3–20.2)
Systemic therapy post-RT (n) Chemotherapy only 1
Chemotherapy and endocrine therapy 2
Endocrine therapy only 12
None 1
DCIS, ductal carcinoma in situ; UO, upper outer; UI, upper inner; LO, lower outer; LI, lower inner; RT, radiotherapy.
aAll invasive tumors were ≤2.0 cm in size. One of the DCIS tumors was 3.0 cm in maximum dimension.
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Table 2 | Dosimetric analysis.
Structure V% isodose Median (range) or n
Ipsilateral breast 105 0.5% (0–12)
100 6% (2–15)
75 13% (8–23)
50 20% (12–31)
25 31% (19–46)
Breast/implant interfacea 100 1% (0–27)
75 7% (0–34)
50 12% (0–40)
25 22% (0–71)
GTV 95 100% (95–100)
90 100% (99–100)
CTV 95 100% (95–100)
90 100% (99–100)
PTV 95 96% (81–100)
90 100% (95–100)
PTV (n) <50 cm3 7
50–100 cm3 8
>100 cm3 1
Breast volume (n) <500 cm3 7
500–1000 cm3 8
>1000 cm3 1
PTV/breast volume 9% (6–14)
Implant volume 344 cm3 (248–527)
PTV/implant volume 17% (7–61)
Total volumeb 997 cm3 (624–2482)
PTV/total volume 6% (3–10)
Implant/total volume 36% (16–57)
V%isodose, volume (%) of organ/structure receiving a specific % of the prescribed
radiation dose; GTV, gross treatment volume, corresponding to the lumpectomy
cavity; CTV, clinical treatment volume; PTV, planning treatment volume.
aA breast/implant interface volume was created by contouring any breast or
implant volume within 5 mm of the actual breast/implant interface.
bTotal volume= combined ipsilateral breast and implant volume.
prescribed dose, then reduced to ≤10% receiving >30% of the
prescribed dose, and eventually further reduced to ≤10% receiv-
ing >20% of the prescribed dose for the remaining cases in this
series after we gained more experience with IGRT. There were
no dose constraints for the breast implant, since its composition
was considered to be inert. Sub-groups of dose–volume data were
compared using the two-sample t test after verifying normality
and compensating for variance.
In both APBI protocols, breast/chest wall pain and cosmesis
were rated by patient at each follow-up. The Phase III pro-
tocol additionally included a pain and cosmesis evaluation at
baseline (post-lumpectomy pre-RT). Patients on the Phase II
protocol were asked to verbally rate pain as none, mild, mod-
erate, or severe, and cosmesis as excellent, good, fair, or poor
without further instructions. Patients on the Phase III proto-
col completed questionnaires. Possible responses for pain were
no pain, mild tenderness or infrequent discomfort, mild fre-
quent pain, moderate and constant pain, severe pain, and pain
requiring hospitalization. Choices for overall appearance and
specifically size, shape/contour, texture/firmness, and skin/color,
were no change or minimal change, slightly different, obviously
different, and drastically different. Cosmesis was also evaluated by
physician at each follow-up (and at baseline on the Phase III pro-
tocol) per RTOG criteria as detailed in RTOG 0413/NSABP B-39
(16). Presumed surgical effects on cosmesis were not excluded.
The National Cancer Institute Common Terminology Crite-
ria for Adverse Events version 3.0 (CTCAE v3.0) was used to
grade toxicities.
RESULTS
PATIENT AND TREATMENT-RELATED CHARACTERISTICS
Sixteen patients treated with EB-APBI in the setting of previous
breast augmentation were evaluated. The median follow-up from
APBI completion was 23.9 months (range, 1.2–58.6). Patient char-
acteristics (see Table 1) included median age of 50.7 years (range,
40.6–62.2) and 9/16 (56.2%) postmenopausal at diagnosis,median
tumor span of 0.75 cm, and 10/16 (62.5%) with final margins of
at least 0.5 cm. The median time from augmentation mammo-
plasty to breast cancer diagnosis was 10.7 years. The majority of
the implants were saline prostheses (n= 13) placed subpectorally
(n= 15). All patients tolerated treatment well and completed a
total dose of 38.5 Gy in 10 equal fractions delivered twice daily
over five consecutive days. Fifteen patients were treated with sys-
temic therapy after APBI completion. All patients remain disease
free at last follow-up.
DOSE–VOLUME ANALYSES
Five cases in this series were treated with 3D-CRT, while the
remaining 11 were treated with IMRT. Table 2 summarizes
the dose–volume data from these 16 cases. The median PTV
was 57 cm3 (range, 34–248). The median ipsilateral breast tis-
sue (including the PTV and excluding the implant) volume was
614 cm3 (range, 269–2073). The median total (breast tissue plus
implant) volume was 997 cm3. The median PTV/ipsilateral breast
volume and PTV/total volume ratios were 9 and 6%, respectively.
Figure 1 shows an example of an approved treatment plan.
Only a small portion of the ipsilateral breast received high per-
centages of the prescribed dose. Table 2 shows dose–volume data
from the 16 treatment plans. The median percentages receiv-
ing 100, 75, 50, and 25% of the prescribed dose (V100, V75,
V50, and V25) to the ipsilateral breast were 6, 13, 20, and 31%,
respectively. The median V105 to the ipsilateral breast was 0.5%
(range, 0–12) and 4.2 cm3 (range, 0–78.3); there was no statistically
significant difference between the V105 values (p= 0.229 for per-
centage volume and p= 0.147 for cubic centimeter) for patients
with ipsilateral breast volume <500 cm3 (n= 7) vs. >500 cm3
(n= 9). V110 to the ipsilateral breast was noted as 0.00016% in
1/16 plans and negligible in all other cases. The median V105
to the total volume (combined breast tissue and implant) was
0.5% (range, 0–10) and 5.5 cm3 (range, 0–113.4). The median
V100, V75, V50, and V25 to the breast-implant interface vol-
ume were 1, 7, 12, and 22%, respectively. The median prescrip-
tion isodose coverage to 95 and 90% of the GTV, CTV, and
PTV structures were high at 100, 100, 100 and 100, 96, 100%,
respectively.
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FIGURE 1 | Sample approved treatment plan.
COSMESIS REPORTED BY PATIENT AND PHYSICIAN
Cosmetic outcomes analyzed both in aggregate and at the
individual case level are represented pictorially in Figure 2 and
summarized in Table 3. Figure 3 shows representative digital
breast photographs taken at ≥12 months after APBI completion;
photos taken at 1 month after APBI were additionally included
for comparison when available. Overall cosmesis was judged by
patient at baseline (Phase III protocol, n= 13) or at 1 month fol-
lowing APBI completion (Phase II protocol, n= 3) as excellent:
3/16, good: 10/16, and fair: 3/16; physician assessment at the same
time points indicated excellent: 14/16, and good: 2/16. Cosmesis
at last follow-up was judged by patient as excellent: 6/16, good:
7/16, fair: 2/16, and poor: 1/16; physician assessment indicated
excellent: 10/16, good: 5/16, and fair: 1/16, with minimal change
in overall cosmesis from baseline to last follow-up within individ-
ual cases, see Figure 2B. There was a high degree of agreement
between the physician- and patient-rated cosmesis at last-follow-
up, with 14/16 having the same rating or varying by one gradation
(e.g., excellent vs. good).
The stability between cosmesis pre-RT and at last follow-up
is confirmed when only cases with pre-RT assessments are con-
sidered. The aggregate excellent/good overall cosmesis as well as
component category results generally remained stable or improved
for the 13 Phase III patients, see Figure 2C. Similarly, com-
parison between individual case level cosmesis at baseline and
last follow-up showed little or no change, see Figure 2D. One
patient (case D in Figure 3) reported a decline of cosmesis by
more than one gradation (e.g., from good at baseline to poor at last
follow-up); however, the treating physician judged her cosmesis as
good at the same time point.
TREATMENT-RELATED TOXICITIES
No capsular contracture, implant rupture, or any other implant-
related complications were observed. No edema or telangiectasia
was reported at last follow-up. Approximately 12 weeks after APBI
completion, one of the patients treated with 3D-CRT developed
a painful red and swollen breast with a persistent seroma treated
empirically with antibiotics, oxycodone for pain, simple aspira-
tion, and ultimately incision and drainage. There was no evidence
of infection by microbiological culture or imaging. Symptoms
were resolved by the next follow-up at ~1 month after last drainage.
Another patient treated with 3D-CRT – who had the highest V105
and the only measurable V110 in these 16 cases – developed grade
2 subcutaneous fibrosis about 6 months after APBI completion;
according to the patient, the pain is “quite manageable with half
a pill of [hydrocodone 5 mg/acetaminophen 300 mg]” as needed,
which she has taken ever since her lumpectomy and also uses it to
manage tamoxifen-related breast tenderness. Of note, this particu-
lar patient continued to judge her cosmetic outcome as good at last
follow-up, noting that the increased thickening has only slightly
altered the contour and firmness of her treated breast, while her
treating physician downgraded her cosmesis to fair due to the
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FIGURE 2 | Cosmesis outcomes. MD= study investigator. *For the three
cases on the Phase II protocol, which did not require a baseline
assessment, values from the 1-month assessment were used as proxy for
baseline. Phase III protocol questionnaire responses were converted as
follows: no change or minimal change=excellent, slightly different=good,
obviously different= fair, drastically different=poor. The median follow-up
from APBI completion for (C,D) was 23.4 months. (A,C) Light blue= poor,
yellow= fair, maroon=good, purple=excellent. (B) Orange with solid
line= patient-rated overall change, green with dotted line=MD-rated overall
change. (D) Hatched circle=median, shaded box= interquartile range,
asterisk=outlier (more than 1.5 x interquartile range below the first quartile
or above the third quartile).
Table 3 | Cosmesis at specific time points.
Visita Patient-rated cosmesis Physician-rated cosmesis
nb Excellent/good nb Excellent/good
Baseline 16 13 (81.2%) 16 16 (100%)
12 months 15 13 (86.7%) 15 15 (100%)
24 months 11 8 (72.7%) 11 11 (100%)
36 months 3 3 (100%) 3 3 (100%)
48 months 3 3 (100%) 3 3 (100%)
60 months 1 1 (100%) 1 1 (100%)
aFrom APBI completion, closest follow-up within ±180 days to time point speci-
fied.
bBreasts with evaluated cosmesis/pain at time point specified.
increased thickening. No other acute or chronic grade 2+ adverse
events, other uses of antibiotics, or pain requiring narcotics were
observed.
Patient-reported breast/chest wall pain outcomes are repre-
sented in Figure 4. Pain was judged by patient questionnaire
at baseline (n= 13) or verbal rating at 1 month following APBI
completion (n= 3) as none: 6/16, and mild: 10/16. Pain at last
follow-up was judged by patient as none: 10/16, mild: 5/16, and
moderate: 1/16 (corresponding to the aforementioned patient
with grade 2 fibrosis). There was no change in patient-rated pain
from baseline to last follow-up in 8/16 cases. Of the eight cases
with a change in pain level, 6/8 reported an improvement (i.e.,
a decrease in pain), and the two remaining patients reported a
change from no pain at baseline to mild (1/16) and moderate
(1/16) pain at last follow-up. The change in pain from baseline to
last follow-up at the individual case level was small among the 13
Phase III patients, see Figure 4B.
DISCUSSION
Since breast-conserving treatment with RT became an accepted
alternative to mastectomy, some investigators have reported on
the use of whole breast irradiation in the setting of previous
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FIGURE 3 | Breast photographs and cosmesis after EB-APBI. aTime from APBI completion >1 month designated as the closest 6 months follow-up time point.
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FIGURE 4 | Pain outcomes. *For the three cases on the phase 2 protocol,
which did not require a baseline assessment, values from the 1 month
assessment were used as proxy for baseline. Phase III protocol questionnaire
responses were converted as follows: no pain=none, mild tenderness or
infrequent discomfort or mild frequent pain=mild; moderate and constant
pain=moderate; severe pain or pain requiring hospitalization= severe.
(A) Yellow=moderate, maroon=mild, purple=none. (B) Orange with solid
line= patient-rated change in pain.
augmentation (2, 4–15). The implications of reported disease con-
trol and cosmetic outcomes have sometimes been obscured due
to heterogeneous populations that have included previously aug-
mented breasts treated with surgery only and no radiation (13, 14),
breasts reconstructed after mastectomy (4, 6, 7, 12), and a wide
array of clinical scenarios including positive surgical margins (9),
locally advanced (10, 11), recurrent (4), and metastatic (5) disease.
These publications have described ~55% rate of painful harden-
ing of the implants after RT, with good/excellent cosmesis ranging
from as low as 1/3 (5) to as high as 100% (6, 12, 15).
The data on the use of APBI in women with prior breast aug-
mentation in the affected breast is even more limited (17–20).
Our previous publication (19) is the only investigation utilizing
external beam rather than brachytherapy, and the only full-length
treatment apart from a few case reports (18, 20). Findings from
these reports of whole breast or partial breast irradiation are
summarized in the Table S1 in Supplementary Material.
Possible explanations for unsatisfactory cosmesis put forth by
these studies include surgical technique used in the augmentation
mammoplasty procedure (2, 4), time from mammoplasty to RT
(4, 6), implant location (retroglandular vs. subpectoral) (5, 9–11,
14), age (6), dose (4, 10), use of bolus or other practices resulting
in dose inhomogeneity (6, 12), use or timing of chemotherapy (9,
11), etc., with little consensus on the impact of any of these factors
on clinical outcomes.
Combining the data presented in this report with previously
reported outcomes from primarily stage 1–2 breast cancer in
patients with previous augmentation (2–10, 12, 14, 15, 17, 18,
20) demonstrate excellent disease control after both whole breast
irradiation and APBI. After 0.5 to over 10 years of follow-up,
cases treated with adjuvant RT generated a crude local failure rate
of 2.3% (5/221) and overall disease free survival rate of 95.5%
(211/221). Cases treated with APBI had a crude local failure of
1.7% (2/120) with no distant failures (17, 18, 20, 21). Although
longer follow-up is necessary, these efficacy rates are certainly com-
parable to rates reported after whole breast irradiation and APBI
in early stage breast cancer in patients without prior breast aug-
mentation. These favorable results support the consideration of
breast-conserving surgery followed by RT, and specifically APBI,
in the setting of previous breast augmentation in early stage breast
cancer patients deemed otherwise suitable for APBI.
Substantial advances in RT planning and delivery have been
made since the initial reports of whole breast irradiation in
patients with prior breast augmentation. The earliest publications
(2–6) included patients treated before the widespread adoption
of CT-based planning with digitally reconstructed radiographs.
While planning details are not described in the reports of whole
breast irradiation, the higher rate of excellent/good cosmesis in
the more recent publications may reflect the increasing usage
of more sophisticated planning and treatment techniques. Every
APBI publication reported utilizing CT-based planning and IGRT
(17–20) to optimize conformality to the PTV while minimiz-
ing hot or cold spots as well as overall dose to implant pros-
theses. Combining our data with other APBI cases in previ-
ously augmented breasts (17, 18, 20) yields an overall rate of
79.2% excellent cosmesis and 95.8% excellent/good cosmesis.
Only 5% of all APBI cases collectively reported in the current
literature developed any new capsular contracture after RT and
none required surgical revision, scar release, or implant removal
(17, 18, 20).
Recent reports of inferior cosmetic outcomes after EB-APBI (in
patients without prior augmentation) have attracted much atten-
tion. Adverse cosmesis and toxicities were initially noted by groups
from Tufts and University of Michigan (26, 27). The large random-
ized Canadian RAPID trial then released interim results showing
that APBI delivered with 3D-CRT was associated with worse cos-
metic outcomes and late radiation changes at 3 years compared
to whole breast irradiation (28). Liss et al. from University of
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Michigan recently provided an update showing further decline
in cosmetic outcome between 2.5 and 5 years of follow-up (29).
Our previous report (30) offered an extensive discussion of the
discrepant cosmesis reported by various EB-APBI studies (30) in
relation to subtle but important differences in treatment parame-
ters, including our use of IGRT utilizing non-migrating fiducials
and the use of mandatory respiratory control in the University
of Michigan trial, as well as lower mean V100 and V50 (30) in
our treatment plans. In their discussion, Liss et al. interpreted our
previously published data (30) as also showing a trend toward
decline in cosmesis over time (29). At first glance, their 5-year out-
comes and interpretation of our previously published data seem
to undercut the longer-term significance of the currently favor-
able cosmetic outcomes presented in this analysis. It is worth
noting, however, that the 41 cases evaluable at 5 years in our
previous report retained a much higher rate of excellent/good
cosmesis compared to the 34 cases from the University of Michi-
gan (87.8 vs. 73.3%). Therefore, even if a continued decline over
time is observed in our EB-APBI studies with longer follow-up, the
cosmetic outcomes – including those in patients with prior aug-
mentation – will likely remain acceptably favorable. Furthermore,
and perhaps more importantly, since whole breast irradiation has
historically demonstrated high rates of capsular contracture and
unsatisfactory cosmesis, APBI, whether delivered with external
beam or brachytherapy, may provide a more palatable alternative
to patients with prior augmentation who prefer breast-conserving
therapy.
In summary, our institutional experience noted no RT-induced
capsular contracture, implant-related fibrosis or complication,
or high rates of unsatisfactory cosmesis previously observed in
some whole breast irradiation studies. We previously demon-
strated the feasibility of using external beam to deliver APBI in
cosmetically augmented breasts (19). EB-APBI is non-invasive
and offers the advantages of decreased procedural trauma to the
breast and relative ease of adoption for most radiation treat-
ment facilities, thus potentially expanding the accessibility of
APBI to more patients with prior augmentation mammoplasty.
The precision required to optimize dose homogeneity and cus-
tomize implant-sparing is particularly amenable to manipulation
with IMRT (23–25, 31). This updated and expanded data series
corroborates and strengthens our previous report that breast-
conserving therapy including APBI in general, and EB-APBI in
particular, is a viable treatment option for patients with prior
breast augmentation.
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